Ceftazidime-avibactam for the treatment of complicated intra-abdominal infections

References

• Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adult and children: guidelines by the surgical infection society and the infectious diseases society of America. Clin Infect Dis. 2010;50:133–164.
   PubMed Web of Science ®Google Scholar
• Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the surgical infection society and the infectious diseases society of America. Surg Infect. 2010;11:79–109.
   PubMed Web of Science ®Google Scholar
• Brook I. Microbiology of polymicrobial abscesses and implications for therapy. J Antimicrob Chemother. 2002;50:805–810.
   PubMed Web of Science ®Google Scholar
• Goldstein EJ, Snydman DR. Intra-abdominal infections: review of the bacteriology, antimicrobial susceptibility and the role of ertapenem in their therapy. J Antimicrob Chemother. 2004;53(Suppl 2):ii29–36.
   PubMedGoogle Scholar
• Hawser S, Hoban DH, Badal RE, et al. Epidemiology and antimicrobial susceptibility of Gram-negative aerobic bacteria causing intra-abdominal infections during 2010-2011. J Chemother. 2015;27:67–73.
   PubMed Web of Science ®Google Scholar
• Roehrborn A, Thomas L, Potreck O, et al. The microbiology of postoperative peritonitis. Clin Infect Dis. 2001;33:1513–1519.
   PubMed Web of Science ®Google Scholar
• Sartelli M, Catena F, Ansaloni L, et al. Complicated intra-abdominal infections in Europe: a comprehensive review of the CIAO study. World J Emerg Surg. 2012;7:36.
   PubMed Web of Science ®Google Scholar
• Montravers P, Lepape A, Dubreuil L, et al. Clinical and microbiological profiles of community-acquired and nosocomial intra-abdominal infections: results of the French prospective, observational EBIIA study. J Antimicrob Chemother. 2009;63:785–794.
   PubMed Web of Science ®Google Scholar
• Marshall JC. Intra-abdominal infections. Microbes Infect. 2004;6:1015–1025.
   PubMed Web of Science ®Google Scholar
• Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013;41:580–637.
   PubMed Web of Science ®Google Scholar
• Sawyer RG, Claridge JA, Nathens AB, et al. Trial of short-course antimicrobial therapy for intra-abdominal infection. N Engl J Med. 2015;372:1996–2005.
   PubMed Web of Science ®Google Scholar
• Montravers P, Gauzit R, Muller C, et al. Emergence of antibiotic-resistant bacteria in cases of peritonitis after intra-abdominal surgery affects the efficacy of empirical antimicrobial therapy. Clin Infect Dis. 1996;23:486–494.
   PubMed Web of Science ®Google Scholar
• Schneider CP, Seyboth C, Vilsmaier M, et al. Prognostic factors in critically ill patients suffering from secondary peritonitis: a retrospective, observational, survival time analysis. World J Surg. 2009;33:34–43.
   PubMed Web of Science ®Google Scholar
• Krobot K, Yin D, Zhang Q, et al. Effect of inappropriate initial empiric antibiotic therapy on outcome of patients with community-acquired intra-abdominal infections requiring surgery. Eur J Clin Microbiol Infect Dis. 2004;23:682–687.
   PubMed Web of Science ®Google Scholar
• Sturkenboom MC, Goettsch WG, Picelli G, et al. Inappropriate initial treatment of secondary intra-abdominal infections leads to increased risk of clinical failure and costs. Br J Clin Pharmacol. 2005;60:438–443.
   PubMed Web of Science ®Google Scholar
• Tellor B, Skrupky LP, Symons W, et al. Inadequate source control and inappropriate antibiotics are key determinants of mortality in patients with intra-abdominal sepsis and associated bacteremia. Surg Infect. 2015;16:785–793.
   PubMed Web of Science ®Google Scholar
• Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis. 2008;197:1079–1081.
   PubMed Web of Science ®Google Scholar
• Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! an update from the infectious diseases society of America. Clin Infect Dis. 2009;48:1–12.
   PubMed Web of Science ®Google Scholar
• Livermore DM, Woodford N. The beta-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter. Trends Microbiol. 2006;14:413–420.
   PubMed Web of Science ®Google Scholar
• Bush K. Bench-to-bedside review: the role of beta-lactamases in antibiotic-resistant Gram-negative infections. Crit Care. 2010;14:224.
   PubMed Web of Science ®Google Scholar
• Bratu S, Landman D, Haag R, et al. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. Arch Intern Med. 2005;165:1430–1435.
   PubMed Web of Science ®Google Scholar
• Nordmann P, Poirel L. Emerging carbapenemases in Gram-negative aerobes. Clin Microbiol Infect. 2002;8:321–331.
   PubMed Web of Science ®Google Scholar
• Bush K, Jacoby GA. Updated functional classification of beta-lactamases. Antimicrob Agents Chemother. 2010;54:969–976.
   PubMed Web of Science ®Google Scholar
• Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev. 2005;18:657–686.
   PubMed Web of Science ®Google Scholar
• Lucasti C, Vasile L, Sandesc D, et al. Phase 2, Dose-ranging study of relebactam with imipenem-cilastatin in subjects with complicated intra-abdominal infection. Antimicrob Agents Chemother. 2016;60:6234–6243.
   PubMed Web of Science ®Google Scholar
• Syue LS, Chen YH, Ko WC, et al. New drugs for the treatment of complicated intra-abdominal infections in the era of increasing antimicrobial resistance. Int J Antimicrob Agents. 2016;47:250–258.
   PubMed Web of Science ®Google Scholar
• Snydman DR, McDermott LA, Jacobus NV. Activity of ceftolozane-tazobactam against a broad spectrum of recent clinical anaerobic isolates. Antimicrob Agents Chemother. 2014;58:1218–1223.
   PubMed Web of Science ®Google Scholar
• Solomkin J, Hershberger E, Miller B, et al. Ceftolozane-tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistane: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI). Clin Infect Dis. 2015;60:1462–1471.
   PubMed Web of Science ®Google Scholar
• Fortaz®(ceftazidime) [package insert] Research Triangle Park. NC: GlaxoSmithKline; 2007.
   Google Scholar
• Berkhout J, Melchers JM, van Mil AC, et al. In vitro activity of ceftazidime-avibactam combination in in vitro checkerboard assays. Antimicrob Agents Chemother. 2015;59:1138–1144.
   PubMed Web of Science ®Google Scholar
• Aktaş Z, Kayacan C, Oncul O. In vitro activity of avibactam (NXL 104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae. Int J Antimicrob Agents. 2012;39:86–89.
   PubMed Web of Science ®Google Scholar
• Livermore DM, Mushtaq S, Warner M, et al. NXL 104 combinations versus Enterobacteriaceae with CTX-M extended-spectrum beta-lactamases and carbapenemases. J Antimicrob Chemother. 2008;62:1053–1056.
   PubMed Web of Science ®Google Scholar
• Endimiani A, Choudhary Y, Bonomo RA. In vitro activity of NXL 104 in combination with beta-lactams against Klebsiella pneumoniae isolates producing KPC carbapenemases. Antimicrob Agents Chemother. 2009;53:3599–3601.
   PubMed Web of Science ®Google Scholar
• Avycaz®(ceftazidime-avibactam) [package insert] Cincinnati. OH: Forest Pharmaceuticals, Inc; 2015.
   Google Scholar
• [cited 2016 June 28]. Available from: https://www.astrazeneca.com/media-centre/press-releases/2016/New-antibiotic-Zavicefta-approved-in-the-European-Union-for-patients-with-serious-bacterial-infections-28062016.htm
   Google Scholar
• Sharma R, Eun Park T, Moy S. Ceftazidime-Avibactam: a novel cephalosporin/β-lactamase inhibitor combination for the treatment of resistant Gram-negative organism. Clin Ther. 2016;38:431–444.
   PubMed Web of Science ®Google Scholar
• Lagacé-Wiens P, Walkty A, Karlowsky JA. Ceftazidime-avibactam: an evidence based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections. Core Evid. 2014;9:13–25.
   PubMedGoogle Scholar
• Zasowski EJ, Rybak JM, Rybak MJ. The β-lactams strike back: ceftazidime-avibactam. Pharmacotherapy. 2015;35:755–770.
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Lawson CD, Adam H, et al. Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination. Drugs. 2013;73:159–177.
   PubMed Web of Science ®Google Scholar
• van Duin D, Bonomo RA. Ceftazidime-avibactam and ceftolozane-tazobactam: second generation β-lactam/β-lactamase inhibitor combinations. Clin Infect Dis. 2016;63:234–241.
   PubMed Web of Science ®Google Scholar
• Ehmann DE, Jahić H, Ross PL, et al. Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor. Proc Natl Acad Sci USA. 2012;109:11663–11668.
   PubMed Web of Science ®Google Scholar
• Kuti JL, Horowitz S, Nightingale CH, et al. Comparison of pharmacodynamic target attainment between healthy subjects and patients for ceftadizime and meropenem. Pharmacotherapy. 2005;25:935–941.
   PubMed Web of Science ®Google Scholar
• Muller AE, Punt N, Mouton JW. Optimal exposures of ceftazidime predict the probability of microbiological and clinical outcome in the treatment of nosocomial pneumonia. J Antimicrob Chemother. 2013;68:900–906.
   PubMed Web of Science ®Google Scholar
• Coleman K, Levasseur P, Girard AM, et al. Activities of ceftazidime and avibactam against β-lactamase producing Enterobacteriaceae in a hollow-fiber pharmacodynamic model. Antimicrob Agents Chemother. 2014;58:3366–3372.
   PubMed Web of Science ®Google Scholar
• Merdjan H, Rangaraju M, Tarral A. Safety and pharmacokinetics of single and multiple ascending doses of avibactam alone and in combination with ceftazidime in healthy male volunteers: results of two randomized, placebo-controlled studies. Clin Drug Investig. 2015;35:307–317.
   PubMed Web of Science ®Google Scholar
• Berkhout J, Melchers MJ, van Mil AC, et al. Pharmacodynamics of ceftazidime and avibactam in neutropenic mice with thigh or lung infection. Antimicrob Agents Chemother. 2015;60:368–375.
   PubMed Web of Science ®Google Scholar
• Dallow J, Otterson LG, Huband MD, et al. Microbiological interaction studies between ceftazidime-avibactam and pulmonary surfactant and between ceftazidime-avibactam and antibacterial agents of other classes. Int J Antimicrob Agents. 2014;44:552–556.
   PubMed Web of Science ®Google Scholar
• Mazuski JE, Gasink LB, Armstrong J, et al. Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, phase 3 program. Clin Infect Dis. 2016;62:1380–1389.
   PubMed Web of Science ®Google Scholar
• Crandon JL, Schuck VJ, Banevicius JA, et al. Comparative in vitro and in vivo efficacies of human simulated doses of ceftazidime and ceftazidime-avibactam against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2012;56:6137–6146.
   PubMed Web of Science ®Google Scholar
• Merdjan H, Tarral A, Das S, et al. Phase 1 study assessing the pharmacokinetic profile and safety of avibactam in patients with renal impairment. J Clin Pharmacol. 2016 Jul 12; [Epub ahead of print]. DOI:10.1002/jcph.793
   PubMedGoogle Scholar
• Tominaga N, Edeki T, Li J, et al. Phase I study assessing the safety, tolerability, and pharmacokinetics of avibactam and ceftazidime-avibactam in healthy Japanese volunteers. J Infect Chemother. 2015;21:551–558.
   PubMed Web of Science ®Google Scholar
• Tarral A, Merdjan H. Effect of age and sex on the pharmacokinetics and safety of avibactam in healthy volunteers. Clin Ther. 2015;37:877–886.
   PubMed Web of Science ®Google Scholar
• Ljungberg B, Nilsson-Ehle I. Comparative pharmacokinetics of ceftazidime in young, healthy and elderly, acutely ill males. Eur J Clin Pharmacol. 1988;34:179–186.
   PubMed Web of Science ®Google Scholar
• Gonҫalves-Pereira J, Pόvoa P. Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams. Crit Care. 2011;15(4):R206. Epub 2011 Sep 13. DOI:10.1186/cc10324
   Google Scholar
• Taccone FS, Laterre PF, Dugernier T, et al. Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock. Crit Care. 2010;14(4):R126. Epub 2010 Jul 1. DOI:10.1186/cc9091
   PubMed Web of Science ®Google Scholar
• Hites M, Taccone FS, Wolff F, et al. Case-control study of drug monitoring of β-lactams in obese critically ill patients. Antimicrob Agents Chemother. 2013;57:708–715.
   PubMed Web of Science ®Google Scholar
• Buijk SL, Gyssens IC, Mouton JW, et al. Pharmacokinetics of ceftazidime in serum and peritoneal exudate during continuous versus intermittent administration to patients with severe intra-abdominal infections. J Antimicrob Chemother. 2002;49:121–128.
   PubMed Web of Science ®Google Scholar
• Lucasti C, Popescu I, Ramesh MK, et al. Comparative study of the efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, phase II trial. J Antimicrob Chemother. 2013;68:1183–1192.
   PubMed Web of Science ®Google Scholar
• Vishwanathan K, Mair S, Gupta A, et al. Assessment of the mass balance recovery and metabolite profile of avibactam in humans and in vitro drug-drug interaction potential. Drug Metab Dispos. 2014;42:932–942.
   PubMed Web of Science ®Google Scholar
• [cited 2016 Feb 24]. Available from: http://www.prnewswire.com/news-releases/fda-accepts-and-grants-priority-review-for-avycaz-ceftazidime-and-avibactam-supplemental-new-drug-application-snda-300225138.html
   Google Scholar
• van Duin D, Doi Y. The global epidemiology of carbapenemase-producing Enterobacteriaceae. Virulence. 2016 Aug 11: 1–10.
   PubMedGoogle Scholar
• Humphries RM, Yang S, Hemarajata P, et al. First report of ceftazidime-avibactam resistance in a KPC-3-expressing Klebsiella pneumoniae isolate. Antimicrob Agents Chemother. 2015;59:6605–6607.
   PubMed Web of Science ®Google Scholar
• Shah PJ, Hanson C, Larson P, et al. Carbapenem-resistant Escherichia coli resistant to ceftazidime-avibactam: the need for a commercially available testing product. Am J Health Syst Pharm. 2016;73:1029–1030.
   PubMed Web of Science ®Google Scholar
• Perez F, Chakhtoura NG, Papp-Wallace KM, et al. Treatment options for infections caused by carbapenem-resistant Enterobacteriaceae: can we apply “precision medicine” to antimicrobial chemotherapy? Expert Opin Pharmacother. 2016;17:761–781.
   PubMed Web of Science ®Google Scholar
• Laxminarayan R, Chaudhury RR. Antibiotic resistance in India: drivers and opportunities for action. PLoS Med. 2016;13(3):e1001974.
   PubMed Web of Science ®Google Scholar